NASP inhibitors constitute a specific chemical class renowned for their distinctive mechanism of action in disrupting the normal functioning of nucleoside phosphorylases. These enzymes are essential players in the intricate network of nucleoside metabolism, driving the conversion of nucleosides into nucleobases and ribose-1-phosphate molecules. The inhibitors within this class are often carefully designed synthetic compounds, each featuring a unique molecular structure that grants them the capability to interact with the catalytic sites of nucleoside phosphorylases. This interaction obstructs the enzyme's ability to facilitate the conversion process by impeding the necessary enzymatic reactions. The precise binding of NASP inhibitors to the active site of nucleoside phosphorylases serves as a key inhibitory step. By forming these specific interactions, the inhibitors essentially halt the enzymatic conversion of nucleosides, disrupting the balance within nucleotide biosynthesis and catabolism pathways.
This perturbation subsequently ripples through various cellular processes that rely on nucleotide availability. Most prominently, the inhibitors' impact on DNA and RNA synthesis processes can reverberate throughout the entire cellular machinery, potentially affecting fundamental biological activities.
The structural diversity inherent in the NASP inhibitors class contributes to their versatility in interactions with nucleoside phosphorylases. By utilizing a spectrum of molecular architectures, these inhibitors can influence the enzymatic activities of various nucleoside phosphorylases in distinct ways. This chemical versatility allows for fine-tuning of inhibitory effects and potentially enables researchers to tailor the inhibitors for specific purposes.
The insights gained from studying NASP inhibitors may unveil novel pathways or processes influenced by nucleotide availability, leading to a deeper understanding of cellular dynamics and potentially even unveiling new avenues for future research and application development.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Fludarabine | 21679-14-1 | sc-204755 sc-204755A | 5 mg 25 mg | $58.00 $204.00 | 15 | |
A compound used for certain cancers by interfering with DNA synthesis through NASP inhibition. | ||||||
2-Chloro-2′-deoxyadenosine | 4291-63-8 | sc-202399 | 10 mg | $144.00 | 1 | |
Also called 2-chlorodeoxyadenosine, used for hairy cell leukemia by incorporating into DNA and inhibiting synthesis. | ||||||
Pentostatin | 53910-25-1 | sc-204177 sc-204177A | 10 mg 50 mg | $175.00 $702.00 | 5 | |
An inhibitor of purine metabolism, primarily used for hairy cell leukemia. | ||||||
Vidarabine Monohydrate | 24356-66-9 | sc-296694 | 1 g | $199.00 | ||
An antiviral agent in research effective against herpes simplex and varicella-zoster infections. | ||||||
2′-Deoxy-2′,2′-difluorocytidine | 95058-81-4 | sc-275523 sc-275523A | 1 g 5 g | $56.00 $128.00 | ||
A chemotherapy agent disrupting DNA synthesis and also indirectly inhibiting NASP. | ||||||
Clofarabine | 123318-82-1 | sc-278864 sc-278864A | 10 mg 50 mg | $185.00 $781.00 | ||
Used for relapsed or refractory acute lymphoblastic leukemia, it incorporates into DNA and hampers synthesis. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $218.00 $322.00 $426.00 | 7 | |
Affects myelodysplastic syndromes (MDS) by altering DNA synthesis pathways through hypomethylation. | ||||||
1-β-D-Arabinofuranosylcytosine | 147-94-4 | sc-201628 sc-201628A sc-201628B sc-201628C sc-201628D | 1 g 5 g 25 g 100 g 250 g | $150.00 $263.00 $518.00 $731.00 $1461.00 | 1 | |
Used for leukemia and lymphoma, it hampers DNA synthesis and repair. | ||||||
Entecavir | 142217-69-4 | sc-204738 sc-204738A sc-204738B | 1 mg 5 mg 25 mg | $77.00 $214.00 $632.00 | 11 | |
Chronic hepatitis B virus infections by inhibiting viral DNA polymerase, indirectly affecting NASP. | ||||||